149 / 1835
ECHELON-1: Phase III Trial
BV + AVD vs. ABVD in frontline advanced cHL
Younes et al, ASCO 2013; Chicago, US (Abstract #TPS8612)
Brentuximab Vedotin
1,2 mg/kg q2w
+
AVD
28-day cycles
ABVD
28-day cycles
R
A
N
D
O
M
I
Z
E
E
V
A
L
U
A
T
I
O
N
* Assessment based on Revised Response Criteria
for Malignant Lymphoma